137 related articles for article (PubMed ID: 16275032)
1. Conformational analyses and docking studies of a series of 5-nitrofuran- and 5-nitrothiophen-semicarbazone derivatives in three possible binding sites of trypanothione and glutathione reductases.
Vega-Teijido M; Caracelli I; Zukerman-Schpector J
J Mol Graph Model; 2006 Mar; 24(5):349-55. PubMed ID: 16275032
[TBL] [Abstract][Full Text] [Related]
2. Docking and molecular dynamics studies at trypanothione reductase and glutathione reductase active sites.
Iribarne F; Paulino M; Aguilera S; Murphy M; Tapia O
J Mol Model; 2002 May; 8(5):173-83. PubMed ID: 12111385
[TBL] [Abstract][Full Text] [Related]
3. Glutathione reductase turned into trypanothione reductase: structural analysis of an engineered change in substrate specificity.
Stoll VS; Simpson SJ; Krauth-Siegel RL; Walsh CT; Pai EF
Biochemistry; 1997 May; 36(21):6437-47. PubMed ID: 9174360
[TBL] [Abstract][Full Text] [Related]
4. Molecular docking of a series of peptidomimetics in the trypanothione binding site of T. cruzi trypanothione reductase.
da Rocha Pita SS; Cirino JJ; de Alencastro RB; Castro HC; Rodrigues CR; Albuquerque MG
J Mol Graph Model; 2009 Nov; 28(4):330-5. PubMed ID: 19766515
[TBL] [Abstract][Full Text] [Related]
5. Design, synthesis and biological evaluation of new potent 5-nitrofuryl derivatives as anti-Trypanosoma cruzi agents. Studies of trypanothione binding site of trypanothione reductase as target for rational design.
Aguirre G; Cabrera E; Cerecetto H; Di Maio R; González M; Seoane G; Duffaut A; Denicola A; Gil MJ; Martínez-Merino V
Eur J Med Chem; 2004 May; 39(5):421-31. PubMed ID: 15110968
[TBL] [Abstract][Full Text] [Related]
6. Structures of tryparedoxins revealing interaction with trypanothione.
Hofmann B; Budde H; Bruns K; Guerrero SA; Kalisz HM; Menge U; Montemartini M; Nogoceke E; Steinert P; Wissing JB; Flohé L; Hecht HJ
Biol Chem; 2001 Mar; 382(3):459-71. PubMed ID: 11347894
[TBL] [Abstract][Full Text] [Related]
7. Specificity of the trypanothione-dependent Leishmania major glyoxalase I: structure and biochemical comparison with the human enzyme.
Ariza A; Vickers TJ; Greig N; Armour KA; Dixon MJ; Eggleston IM; Fairlamb AH; Bond CS
Mol Microbiol; 2006 Feb; 59(4):1239-48. PubMed ID: 16430697
[TBL] [Abstract][Full Text] [Related]
8. Structural insights into the enzymes of the trypanothione pathway: targets for antileishmaniasis drugs.
Colotti G; Baiocco P; Fiorillo A; Boffi A; Poser E; Chiaro FD; Ilari A
Future Med Chem; 2013 Oct; 5(15):1861-75. PubMed ID: 24144416
[TBL] [Abstract][Full Text] [Related]
9. Active site of trypanothione reductase. A target for rational drug design.
Hunter WN; Bailey S; Habash J; Harrop SJ; Helliwell JR; Aboagye-Kwarteng T; Smith K; Fairlamb AH
J Mol Biol; 1992 Sep; 227(1):322-33. PubMed ID: 1522596
[TBL] [Abstract][Full Text] [Related]
10. Assaying phenothiazine derivatives as trypanothione reductase and glutathione reductase inhibitors by theoretical docking and molecular dynamics studies.
Iribarne F; Paulino M; Aguilera S; Tapia O
J Mol Graph Model; 2009 Nov; 28(4):371-81. PubMed ID: 19801198
[TBL] [Abstract][Full Text] [Related]
11. Redox enzyme engineering: conversion of human glutathione reductase into a trypanothione reductase.
Bradley M; Bücheler US; Walsh CT
Biochemistry; 1991 Jun; 30(25):6124-7. PubMed ID: 2059620
[TBL] [Abstract][Full Text] [Related]
12. Trypanosoma cruzi: effect and mode of action of nitroimidazole and nitrofuran derivatives.
Maya JD; Bollo S; Nuñez-Vergara LJ; Squella JA; Repetto Y; Morello A; Périé J; Chauvière G
Biochem Pharmacol; 2003 Mar; 65(6):999-1006. PubMed ID: 12623132
[TBL] [Abstract][Full Text] [Related]
13. Catalysis and structural properties of Leishmania infantum glyoxalase II: trypanothione specificity and phylogeny.
Silva MS; Barata L; Ferreira AE; Romão S; Tomás AM; Freire AP; Cordeiro C
Biochemistry; 2008 Jan; 47(1):195-204. PubMed ID: 18052346
[TBL] [Abstract][Full Text] [Related]
14. Crystal structure of glutathione reductase Glr1 from the yeast Saccharomyces cerevisiae.
Yu J; Zhou CZ
Proteins; 2007 Sep; 68(4):972-9. PubMed ID: 17554778
[TBL] [Abstract][Full Text] [Related]
15. Computational sampling of a cryptic drug binding site in a protein receptor: explicit solvent molecular dynamics and inhibitor docking to p38 MAP kinase.
Frembgen-Kesner T; Elcock AH
J Mol Biol; 2006 May; 359(1):202-14. PubMed ID: 16616932
[TBL] [Abstract][Full Text] [Related]
16. Understanding nicotinamide dinucleotide cofactor and substrate specificity in class I flavoprotein disulfide oxidoreductases: crystallographic analysis of a glutathione amide reductase.
Van Petegem F; De Vos D; Savvides S; Vergauwen B; Van Beeumen J
J Mol Biol; 2007 Dec; 374(4):883-9. PubMed ID: 17977556
[TBL] [Abstract][Full Text] [Related]
17. Engineering the substrate specificity of glutathione reductase toward that of trypanothione reduction.
Henderson GB; Murgolo NJ; Kuriyan J; Osapay K; Kominos D; Berry A; Scrutton NS; Hinchliffe NW; Perham RN; Cerami A
Proc Natl Acad Sci U S A; 1991 Oct; 88(19):8769-73. PubMed ID: 1924337
[TBL] [Abstract][Full Text] [Related]
18. Isatin 3-semicarbazone and 1-methylisatin 3-semicarbazone.
Pelosi G; Pelizzi C; Belicchi Ferrari M; Rodríguez-Argüelles MC; Vieito C; Sanmartín J
Acta Crystallogr C; 2005 Oct; 61(Pt 10):o589-92. PubMed ID: 16210765
[TBL] [Abstract][Full Text] [Related]
19. Conformational dynamics of the estrogen receptor alpha: molecular dynamics simulations of the influence of binding site structure on protein dynamics.
Celik L; Lund JD; Schiøtt B
Biochemistry; 2007 Feb; 46(7):1743-58. PubMed ID: 17249692
[TBL] [Abstract][Full Text] [Related]
20. Molecular docking studies of selected tricyclic and quinone derivatives on trypanothione reductase of Leishmania infantum.
Venkatesan SK; Shukla AK; Dubey VK
J Comput Chem; 2010 Oct; 31(13):2463-75. PubMed ID: 20340105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
